细胞外基质在胰腺癌中的作用机制及治疗靶点研究进展

doi:10.11904/j.issn.1002-3070.2025.06.011

Abstract

Abstract: Pancreatic cancer is a malignant tumor of digestive tract with an extremely poor prognosis.It is highly invasiveness and drug resistance.The 5-year survival rate of patients is only approximately 10%.Currently,Surgical resection,chemotherapy,and radiotherapy are the standard treatment methods,but there are still many limitations and are prone to tumor recurrence and drug resistance.Therefore,exploring new therapeutic targets has become an urgent need in current research.As a key component of tumor microenvironment,the extracellular matrix plays an important role in the progression and drug resistance of pancreatic cancer.Recent studies have shown that targeted intervention of the extracellular matrix is expected to bring new breakthroughs in the treatment of pancreatic cancer.Based on the latest research progress at domestically and abroad,this paper systematically reviews the theoretical basis of extracellular matrix as a therapeutic target for pancreatic cancer.

Key words: pancreatic cancer, extracellular matrix, tumor microenvironment, tumor resistance, targeted therapy

CLC Number:

R735.9

ZHAO Zhilong, HOU Junming. Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer[J]. Journal of Practical Oncology, 2025, 39(6): 535-541.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.06.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I6/535

References

1 Chakraborty A,Halder B,Mondal S,et al.NADPH oxidase 1 in chronic pancreatitis-activated pancreatic stellate cells facilitates the progression of pancreatic cancer[J].Am J Cancer Res,2023,13(1):118-142.
2 Li BQ,Liu XY,Mao T,et al.The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis[J].Front Oncol,2022,12:1050274.
3 Munigala S,Almaskeen S,Subramaniam DS,et al.Acute pancreatitis recurrences augment long-term pancreatic cancer risk[J].Am J Gastroenterol,2023,118(4):727-737.
4 Liu Z,Hiromitsu H,Kazuki M,et al.Biological and clinical impacts of glucose metabolism in pancreatic ductal adenocarcinoma[J].Cancers(Basel),2023,15(2):498.
5 Popovic K,Smolović B,Martinović M,et al.The relationship between diabetes mellitus and pancreatic cancer-diabetes mellitus as a red flag for pancreatic cancer[J].Cancer Epidemiol Biomarkers Prev,2023,32(3):298-305.
6 Ruze R,Chen Y,Xu R,et al.Obesity,diabetes mellitus,and pancreatic carcinogenesis:correlations,prevention,and diagnostic implications[J].Biochim Biophys Acta Rev Cancer,2023,1878(1):188844.
7 Waleleng BJ,Adiwinata R,Wenas NT,et al.Screening of pancreatic cancer:target population,optimal timing and how[J]? Ann Med Surg(Lond),2022,84:104814.
8 胰腺癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1117-1136.
9 Cronin KA,Scott S,Firth AU,et al.Annual report to the nation on the status of cancer,part 1:national cancer statistics[J].Cancer,2022,128(24):4251-4284.
10 Xiang H,Yang R,Tu J,et al.Metabolic reprogramming of immune cells in pancreatic cancer progression[J].Biomed Pharmacother,2023,157:113992.
11 Kim J.Cell dissemination in pancreatic cancer[J].Cells,2022,11(22):3683.
12 Koustas E,Trifylli EM,Sarantis P,et al.The emerging role of microRNAs and autophagy mechanism in pancreatic cancer progression:future therapeutic approaches[J].Genes(Basel),2022,13(10):1868.
13 Tiwari A,Trivedi R,Lin SY.Tumor microenvironment:barrier or opportunity towards effective cancer therapy[J].J Biomed Sci,2022,29(1):83.
14 Jiang J,Mei J,Yi S,et al.Tumor associated macrophage and microbe:the potential targets of tumor vaccine delivery[J].Adv Drug Deliv Rev,2022,180:114046.
15 Singh M,Pal P,Dutta RS,et al.Nanodiamond mediated molecular targeting in pancreatic ductal adenocarcinoma:disrupting the tumor-stromal cross-talk,next hope on the horizon?[J].Curr Cancer Drug Targets,2023,23(8):620-633.
16 Yuan Z,Li Y,Zhang S,et al.Extracellular matrix remodeling in tumor progression and immune escape:from mechanisms to treatments[J].Mol Cancer,2023,22(1):48.
17 Peiffer R,Boumahd Y,Gullo C,et al.Cancer-associated fibroblast diversity shapes tumor metabolism in pancreatic cancer[J].Cancers(Basel),2022,15(1):61.
18 Ge W,Yue M,Wang Y,et al.A novel molecular signature of cancer-associated fibroblasts predicts prognosis and immunotherapy response in pancreatic cancer[J].Int J Mol Sci,2022,24(1):156.
19 Bryce AS,Dreyer SB,Froeling FEM,et al.Exploring the biology of cancer-associated fibroblasts in pancreatic cancer[J].Cancers(Basel),2022,14(21):5302.
20 Shinkawa T,Ohuchida K,Nakamura M.Heterogeneity of cancer-associated fibroblasts and the tumor immune microenvironment in pancreatic cancer[J].Cancers(Basel),2022,14(16):3994.
21 Yang XY,Zhang JG,Zhou QM,et al.Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer[J].J Nanobiotechnology,2022,20(1):524.
22 Liu X,Iovanna J,Santofimia-Castaño P.Stroma-targeting strategies in pancreatic cancer:a double-edged sword[J].J Physiol Biochem,2023,79(1):213-222.
23 Papalazarou V,Drew J,Juin A,et al.Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche[J].J Cell Sci,2022,135(24):jcs259978.
24 Madsen EA,Thorlacius-Ussing J,Nissen NI,et al.Type XXII collagen complements fibrillar collagens in the serological assessment of tumor fibrosis and the outcome in pancreatic cancer[J].Cells,2022,11(23):3763.
25 Ko S,Jung KH,Yoon YC,et al.A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer[J].Am J Cancer Res,2022,12(9):4326-4342.
26 Ding C,Yu Z,Liu X,et al.Collagen type VII α1 chain:a promising prognostic and immune infiltration biomarker of pancreatic cancer[J].Oncol Lett,2023,25(2):77.
27 Jørgensen C.Untangling the tumorigenic role of homotrimeric collagen I[J].Cancer Cell,2022,40(8):802-804.
28 Chen Y,Yang S,Tavormina J,et al.Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer[J].Cancer Cell,2022,40(8):818-834.e9.
29 Jiang C,Wang M,Yao W,et al.Comprehensive analysis on prognosis and immune infiltration of lysyl oxidase family members in pancreatic adenocarcinoma with experimental verification[J].Front Mol Biosci,2022,9:778857.
30 Coffelt SB,Morton JP.LOXL2 in pancreatic tumourigenesis:the complexity of tumour-stromal crosstalk exemplified[J].Gut,2023,72(2):221-222.
31 Alonso-Nocelo M,Ruiz-Cañas L,Sancho P,et al.Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma[J].Gut,2023,72(2):345-359.
32 Minici C,Rigamonti E,Lanzillotta M,et al.B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma[J].Oncoimmunology,2020,9(1):1794359.
33 Murphy JE,Wo JY,Ryan DP,et al.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer:a phase 2 clinical trial[J].JAMA Oncol,2019,5(7):1020-1027.
34 Reis JSD,Santos MARDC,da Costa KM,et al.Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells[J].Matrix Biol,2023,118:47-68.
35 Sato N,Kohi S,Hirata K,et al.Role of hyaluronan in pancreatic cancer biology and therapy:once again in the spotlight[J].Cancer Sci,2016,107(5):569-575.
36 Kobayashi T,Chanmee T,Itano N,et al.Hyaluronan:metabolism and function[J].Biomolecules,2020,10(11):1525.
37 Jiang Y,Zhang H,Wang J,et al.Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy[J].J Hematol Oncol,2022,15(1):34.
38 Caon I,Bartolini B,Parnigoni A,et al.Revisiting the hallmarks of cancer:the role of hyaluronan[J].Semin Cancer Biol,2020,62:9-19.
39 Nakano M,Taguchi R,Kikushige Y,et al.RHAMM marks proliferative subpopulation of human colorectal cancer stem cells[J].Cancer Sci,2023,114(7):2895-2906.
40 Markowska A,Antoszczak M,Markowska J,et al.CEMIP-mediated hyaluronan metabolism facilitates SCLC metastasis by activating TLR2/c-Src/ERK1/2 axis[J].Biochim Biophys Acta Mol Cell Res,2023,1870(5):119451.
41 Maksym A,Mielczarek-Palacz A,Mika J,et al.Role of hyaluronic acid in selected malignant neoplasms in women[J].Biomedicines,2023,11(2):304.
42 Yang YM,Noureddin M,Liu C,et al.Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis[J].Sci Transl Med,2019,11(496):eaat9284.
43 Wiedmann L,De Angelis Rigotti F,Vaquero-Siguero N,et al.HAPLN1 potentiates peritoneal metastasis in pancreatic cancer[J].Nat Commun,2023,14(1):2353.
44 Van Cutsem E,Tempero MA,Sigal D,et al.Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma[J].J Clin Oncol,2020,38(27):3185-3194.
45 Ko AH,Kim KP,Siveke JT,et al.Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer:MORPHEUS phase Ib/II umbrella randomized study platform[J].Oncologist,2023,28(6):553-e472.
46 Qin W,Zhang J,Rong R,et al.Osteoglycin(OGN)promotes tumorigenesis of pancreatic cancer cell via targeting ID4[J].Tissue Cell,2022,78:101867.
47 Hurtado de Mendoza T,Mose ES,Botta GP,et al.Tumor-penetrating therapy for β5 integrin-rich pancreas cancer[J].Nat Commun,2021,12(1):1541.
48 Su L,Chen Y,Huang C,et al.Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models[J].Sci Transl Med,2023,15(678):eabl7895.
49 Yu P,Zhang X,Liu N,et al.Pyroptosis:mechanisms and diseases[J].Signal Transduct Target Ther,2021,6(1):128.
50 Cheng C,Liu D,Liu Z,et al.Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer[J].Cancer Sci,2022,113(9):2986-3001.
51 Malsy M,Hofer V,Schmidbauer S,et al.Effects of ketamine,S-ketamine and MK 801 on integrin beta-3-mediated cell migration in pancreatic carcinoma[J].J Cancer Sci Clin Ther,2022,6(4):446-451.
52 Rapetti-Mauss R,Nigri J,Berenguier C,et al.SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer[J].Gut,2023,72(4):722-735.
53 Gregori A,Bergonzini C,Capula M,et al.Prognostic significance of integrin subunit alpha 2(ITGA2)and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma(PDAC)[J].Cancers(Basel),2023,15(3):628.
54 Wu C,Rakhshandehroo T,Wettersten HI,et al.Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation[J].Nat Cell Biol,2023,25(2):309-322.
55 Tomas Bort E,Joseph MD,Wang Q,et al.Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion[J].Elife,2023,12:e86971.
56 Wang Y,Wang S,Liu M,et al.The function of NAT10-driven N4-acetylcytidine modification in cancer:novel insights and potential therapeutic targets[J].Cell Biosci,2025,15(1):165.
57 Mortensen REJ,Holmström MO,Lisle TL,et al.Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy[J].J Immunother Cancer,2023,11(3):e006432.
58 Liu H,Chen B,Zardi L,et al.Soluble fibronectin promotes migration of oral squamous-cell carcinoma cells[J].Int J Cancer,1998,78(2):261-267.
59 Liu Y,Sinjab A,Min J,et al.Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics[J].Cancer Cell,2025,43(5):905-924.e6.
60 Zhang L,Liu C,Gao H,et al.Study on the expression profile and role of decorin in the progression of pancreatic cancer[J].Aging(Albany NY),2021,13(11):14989-14998.
61 Li H,Chiang CL,Kwak KJ,et al.Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis[J].Adv Sci(Weinh),2024,11(11):e2306373.

[1]	CAI Yiqing, DAI Enyong. Recent progress on molecular targeted therapy for gastric cancer [J]. Journal of Practical Oncology, 2025, 39(6): 542-550.
[2]	XIN Xin, XIONG Wenjing, ZHANG Chunnuan, LI Xiaojing, GAO Xue, ZHANG Yue. Lactylation modification:an emerging target in cancer therapy [J]. Journal of Practical Oncology, 2025, 39(5): 433-436.
[3]	LI Dongsheng, LI Zehao, CHEN Yonggang. Application of DNA methylation risk scoring model for ferroptosis related genes in the prognosis and immune feature assessment of colon cancer [J]. Journal of Practical Oncology, 2025, 39(3): 224-234.
[4]	YE Qianni, LI Juan, WANG Falin, LIU Jiaren. Research progress on the role of phytochemicals in tumor microenvironment [J]. Journal of Practical Oncology, 2025, 39(3): 245-250.
[5]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[6]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[7]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.
[8]	LUO Tingfan, SUN Pengfei. Research progress of macrophages/microglia in the microenvironment of glioma [J]. Journal of Practical Oncology, 2023, 37(5): 443-448.
[9]	CAO Yingyue, PANG Luyi, ZHANG Jian, JIN Shi. The role of cancer-associated fibroblasts in the progression of non-small cell lung cancer [J]. Journal of Practical Oncology, 2023, 37(4): 383-388.
[10]	XU Ting, CHENG Hua, ZHANG Wei. Research progress in the early diagnosis and minimally invasive surgical treatment of elderly pancreatic cancer [J]. Journal of Practical Oncology, 2023, 37(3): 257-261.
[11]	LUN Lixin, ZHONG Zhenbin, ZHAO Xinyu, WU Chou, HAO Chuncheng. Research progress of anti-EGFR therapy in head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 276-280.
[12]	LIU Xinxin, MA Xiyuan, MIU Meiqi, WANG Yuqing, CHEN Jing. Research progress on the role of IL-6 and its receptor in the treatment of breast cancer [J]. Journal of Practical Oncology, 2023, 37(2): 149-154.
[13]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[14]	ZHANG Shumin, ZHANG Gong. Research progress of ILC2s in tumor immune regulation [J]. Journal of Practical Oncology, 2022, 36(6): 566-569.
[15]	LI Xiong, JIANG Wenkai, LANG Zekun, RUI Shaozhen. Research progress on the relationship between tumor-associated neutrophils and pancreatic cancer [J]. Journal of Practical Oncology, 2022, 36(5): 458-462.

Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments